Pharmacodynamics of high-dose chemotherapy

Current Drug Metabolism

Volumn 2, Issue 1, 2001, Pages 53-66

  Nieto, Y ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MITOXANTRONE; PACLITAXEL; THIOTEPA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; BRAIN DISEASE; BRAIN TUMOR; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; HEART MUSCLE NECROSIS; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; LIVER; LIVER DISEASE; LIVER VENOOCCLUSIVE DISEASE; LYMPHOMA; MELANOMA; MUCOSA INFLAMMATION; MYELOID LEUKEMIA; MYELOMA; NEUTROPENIA; OVARY CANCER; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; STEM CELL TRANSPLANTATION; STOMATITIS; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS;

EID: 0035042981     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389200013338720     Document Type: Article

References (56)

1. An overview of cyclophosphamide development and clinical applications
2. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients
3. Nonlinear pharmacokinetics of cyclophosphamide and 4- hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation
4. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients
5. Inhibition of human aldehyde dehydrogenase 1 by the 4- hydroxycyclophosphamidedegradation product acrolein
6. Clinical pharmacokinetics of cyclophosphamide
7. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation
8. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-nitrosourea
9. Metabolic jeopardy with high-dose cyclophosphamide? - Not so fast
10. Quantitation of 4-hydroxycyclophosphamide/ aldophosphamide in whole blood
11. Oxime derivatives of the intermediary oncostatic metabolites of cyclophosphamide and ifosfamide: Synthesis and deuterium labeling for applications to metabolite quantification
12. Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection
13. Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumor response
14. Correlation of high-dose cyclophosphamide (CPA), cisplatin (CDDP), and carmustine (BCNU) pharmacokinetics (PK) to response and toxicity in patients with primary breast cancer
15. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease
16. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) in breast cancer patients
17. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22
18. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
19. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism
20. Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines
21. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
22. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma
23. Amifostine cytoprotection of escalating doses of melphalan and autologous hematopoietic stem cell transplantation: A phase I-II study
24. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma
25. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure
26. Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: Follow-up of 725 patients from a single centre over a period of 26 years
27. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer
28. Oral melphalan kinetics
29. Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion
30. Kinetics of intravenous melphalan
31. Influence of renal failure on myelosupressive effects of melphalan: Cancer and Leukemia Group B experience
32. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer
33. The antitumor activity of melphalan and its hydrolysis products
34. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs
35. Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study
36. Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study
37. High-dose melphalan dosage adjustment: Possibility of using a test dose
38. Pharmacokinetically guided dosing for intravenous melphalan: A pilot study in patients with advanced ovarian adenocarcinoma
39. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
40. Randomized phase III trial of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes
41. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy
42. -triethylenthiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography
43. Busulfan dose adjustment decreases the risk of venoocclusive disease in patients undergoing bone marrow transplantation
44. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
45. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy
46. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)
47. Stem cell transplantation for Non-Hodgkin's lymphomas after IV busulfan and cyclophosphamide
48. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I therapy
49. Pharmacokinetically based individualized IV busulfan therapy in marrow transplant regimens
50. Human CD34 hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNAalkyltransferase and are sensitive to O6-benzylguanine plus BCNU
51. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: Pharmacodynamic evaluation of carmustine
52. Cyclophosphamide, cisplatin and carmustine: Pharmacokinetics of carmustine following multiple alkylating-agent interactions
53. Clinical toxicities encountered with paclitaxel
54. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: A phase I trial
55. Acute encephalopathy: A new toxicity associated with high-dose paclitaxel
56. Phase I trial of docetaxel combined with fixed doses of melphalan and carboplatin, with peripheral blood progenitor cell support in refractory malignancies